Safety and immunogenicity of BPV‐1 L1 virus‐like particles in a dose‐escalation vaccination trial in horses

Hainisch, Edmund K.; Brandt, Sabine; Shafti-Keramat, Saeed; Hoven, R. van den; Kirnbauer, Reinhard

doi:10.1111/j.2042-3306.2011.00390.x

Cited by 36 publications

(36 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Neutralization titers were induced at levels that correlate with protection in both, experimental animals and man. 87 Induction of a protective immune response was also previously reported in cattle (reviewed in Ref. 88), rabbits (cottontail rabbit papillomavirus, CRPV) 89 and dogs (canine oral papillomavirus).…”

Section: Papillomavirusesmentioning

confidence: 78%

Virus-like particle-based vaccines for animal viral infections

Crisci

Bárcena²,

Montoya

2013

Inmunología

View full text Add to dashboard Cite

i n m u n o l o g í a . 2 0 1 3;3 2(3):102-116 103Por lo general son antigénicamente indistinguibles de los virus de los que proceden y su empleo como inmunógenos presenta importantes ventajas en términos de seguridad. Las VLPs pueden inducir una fuerte respuesta inmune, tanto humoral como celular, y se ha demostrado que poseen capacidad de actuar como adyuvantes (self-adjuvanting). Además de su idoneidad como vacunas frente al virus homólogo del cual proceden, las VLPs también se pueden utilizar como vectores para la presentación multimérica de antígenos heterólogos. Las VLPs han mostrado una elevada eficacia como candidatos vacunales, sin embargo, hasta el momento sólo una vacuna basada en VLPs ha sido autorizada y comercializada en el campo veterinario. En este trabajo se revisa el estado actual de las VLP empleadas como nuevas estrategias vacunales en el campo de la veterinaria, analizando las potenciales ventajas y desafíos que enfrenta esta tecnología.

show abstract

Section: Papillomavirusesmentioning

confidence: 78%

Virus-like particle-based vaccines for animal viral infections

Crisci

Bárcena²,

Montoya

2013

Inmunología

View full text Add to dashboard Cite

show abstract

“…Despite a robust humoural response against L1 [60] and a tendency for tumour regression in some animals, results were not conclusive. However, very recently, BPV-1 L1 VLPs were tested in a dose-escalation trial for the vaccination of healthy horses and were shown to induce a long-lasting humoural response, which the authors deemed appropriate for protection [8].…”

Section: Prophylactic and Therapeutic Vaccinesmentioning

confidence: 99%

“…Research on BPV has led to most of the recent breakthroughs on the biology and pathology of animal papillomavirus, with major implications for human health. Using such spontaneous models, researchers have recently made significant discoveries on the interaction of papillomavirus with chemical carcinogens and immunosuppressants [4], on the role of BPV oncoproteins in cell transformation and immune evasion, on the infection of some unusual cell types and the possibility of haematogenous transplacental BPV transmission [5], as well as on new prophylactic and therapeutic vaccines [6][7][8].…”

Section: Introductionmentioning

confidence: 99%

Bovine papillomavirus: opening new trends for comparative pathology

Costa

Medeiros

2013

Arch Virol

View full text Add to dashboard Cite

“…A recent study has shown that intramuscular vaccination of horses with bovine papillomavirus (BPV-1) L1-VLPs results in a long-lasting antibody response against the virus. Neutralization titres were induced at levels that correlate with protection in both, experimental animals and man (Hainisch et al, 2012). Induction of a protective immune response was also previously reported in cattle (reviewed in (Campo, 1997)), rabbits (cottontail rabbit papillomavirus CRPV) (Breitburd et al, 1995) and dogs (canine oral papillomavirus) (Suzich et al, 1995).…”

Section: Animal Virus Vlps As Vaccine Immunogensmentioning

confidence: 57%

Virus-like particles: The new frontier of vaccines for animal viral infections

Crisci

Bárcena²,

Montoya

2012

Veterinary Immunology and Immunopathology

141

116

View full text Add to dashboard Cite

Vaccination continues to be the main approach to protect animals from infectious diseases. Until recently, all licensed vaccines were developed using conventional technologies. Subunit vaccines are, however, gaining attention from researchers in the field of veterinary vaccinology, and among these, virus-like particles (VLPs) represent one of the most appealing approaches. VLPs are robust protein cages in the nanometer range that mimic the overall structure of the native virions but lack the viral genome. They are often antigenically indistinguishable from the virus from which they were derived and present important advantages in terms of safety. VLPs can stimulate strong humoral and cellular immune responses and have been shown to exhibit self-adjuvanting abilities. In addition to their suitability as a vaccine for the homologous virus from which they are derived, VLPs can also be used as vectors for the multimeric presentation of foreign antigens. VLPs have therefore shown dramatic effectiveness as candidate vaccines. Here, we review the current status of VLPs as a vaccine technology in the veterinary field, and discuss the potential advantages and challenges of this technology.

show abstract

Safety and immunogenicity of BPV‐1 L1 virus‐like particles in a dose‐escalation vaccination trial in horses

Abstract: BPV-1 L1 VLPs constitute a promising vaccine candidate for prevention of BPV-1/-2-induced disease in equids.

Cited by 36 publications

References 39 publications

Virus-like particle-based vaccines for animal viral infections

Virus-like particle-based vaccines for animal viral infections

Bovine papillomavirus: opening new trends for comparative pathology

Virus-like particles: The new frontier of vaccines for animal viral infections

Contact Info

Product

Resources

About